Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/56—Materials from animals other than mammals
  • A61K35/63—Arthropods
  • A61K35/64—Insects, e.g. bees, wasps or fleas
  • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
  • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

• the present application relates to a gel composition. More specifically, the application relates to a storage stable and natural based composition containing honey that has a gel structure and, on application to a wound, forms a skin over the wound.
• honey is a naturally sticky substance that if applied to a wound can be difficult to apply and runny. Solutions have is been proposed in the art to overcome this drawback of honey and yet still maintain the honey efficacy in wound treatment.
• the honey composition is a gel paste or ointment that can be easily packaged in a tube or other pliable container.
• the gel can easily be squeezed out of the tube and applied to a wound.
• the gel described in U.S. Published Application No. 2010/0233283 forms a skin over the wound, keeps its shape when applied to a wound (i.e. does not melt or run), and is easier to apply than pure honey. Further, the composition still retains sufficient honey to provide the desired honey antibacterial and wound healing effects.
• a drawback of the composition as described in U.S. Published Application No. 2010/0233283 is that the composition when stored in the container over time can separate, particularly at temperatures over 3000. This is undesirable as separation reduces efficacy and aesthetic characteristics of the gel.
• Natural based products may also be desirable in many applications, sometimes for improved efficacy and often to aid in marketing the products as being natural based and therefore able to be used in a variety nutraceutical applications.
• a further drawback of the composition described in U.S. Published Application No. 2010/0233283 is that it uses a non-natural ingredient being an ethoxylated oil or PEG60.
• the application broadly relates to a composition containing honey for use in wound dressings.
• the composition has a gel consistency that, on application to a wound forms skin over the wound.
• the composition is shelf stable and uses naturally produced products.
• composition for treating a patient wherein the composition comprises:
• a gel composition consisting of:
• compositions have been found to have a far higher level of stability than existing art compositions.
• the applicant has noted a stability of over 5 weeks at 40° C. or at least 9 weeks when stored at 30° C., well beyond that of similar products that became unstable and separated after only 12 hours.
• a further advantage is that the compositions are naturally derived and do not use synthetically derived ingredients.
• compositions have applications as a wound gel stored in a tube and applied to the wound by dispensing the gel from the tube and then applying the gel to the wound surface.
• the composition acts to block egress of debris from outside the wound into the wound and, due to the antimicrobial and healing effects of honey, acts to prevent infection and assist wound healing. Since the honey levels in the composition can be kept high, the efficacy due the honey is retained. Conversely, the other ingredients used avoid other difficulties associated with using honey such as being difficult to apply due to it's stickiness and the fact that body temperature causes the honey to run or flow from the wound.
• a further advantage of the above composition is that it may be irradiated using standard conditions with no loss in stability of other characteristics including efficacy.
• the art teaches about the difficulties of irradiation and how irradiation can reduce the efficacy, stability and physical properties of honey based compositions. Irradiation is however essential and an accepted form of sterilising honey based compositions used in wound healing. In the applicant's experience, irradiation of the honey based composition described herein does not alter the characteristics of the composition including stability.
• the application broadly relates to a composition containing honey for use in wound dressings.
• the composition has a gel consistency that, on application to a wound forms skin over the wound.
• the composition is shelf stable and uses naturally produced products.
• surfactant refers to a compound that is a wetting agent that reduces the surface tension of a liquid. Surfactants reduce the interfacial tension between oil and water by adsorbing at the liquid-liquid interface.
• gel refers to a fluidity that lies between a liquid and solid and may incorporate a degree of viscoelasticity.
• stable refers to the composition remaining in suspension and not undergoing physical, chemical, microbial growth change, or any loss in antibacterial action when stored for a period of time.
• UMF and ‘non-peroxide activity’ refer to the activity of honey not directly attributable to the antimicrobial effects of honey conferred from the normal honey pH and osmolarity, for example that observed and measured in a naturally derived clover honey.
• honey or honey derivative refers to naturally derived honey or mixtures of honey but may also include honey analogues or derivatives such as sugar syrup solutions.
• honey analogue refers to a sugar syrup solution approximating that of honey e.g. including glucose, fructose, water and either hydrogen peroxide and/or one or more hydrogen peroxide precursors.
• glucoside in this specification may be used interchangeably with the term ‘glycoside’.
• the term ‘sterilisation effective dosage of radiation’ refers to a dose of radiation being at least 1 kGy or ideally 10 kGy or higher.
• natural based refers to compounds obtained from nature or one or more synthesised versions of compounds found in nature.
• the compound or compounds used meet the Natural Products Association (NPA) guidelines i.e. they are derived from renewable sources in nature’ they do not use petroleum compounds, they meet generally recognised as safe or GRAS standard as set by the USA FDA and they are manufactured based on NPA approved processes.
• NPA Natural Products Association
• composition for treating a patient wherein the composition comprises:
• the composition has an unexpected and improved stability over the art.
• the composition is stable for at least 8 days when stored at 40° C.
• the composition is stable for at least 21 days when stored at 40° C.
• the composition is stable for at least 9 weeks when stored at 30° C.
• the composition is stable for at least 15 weeks at 30° C.
• the anticipated stability when stored at typical ambient conditions is likely to be at least 3 years based on accelerated trials completed by the applicant. This degree of stability goes well beyond that observed by the applicants for equivalent compositions containing honey, particularly those that have a gel viscosity. For example, in the applicant's experience, the closest similar composition becomes unstable and phase separates after only 12 hours when stored at 40° C.
• the composition is a gel. Gels are a useful consistency for application to wounds as the gel can easily by packaged, dispersed form the packaging and applied to almost any shaped wound.
• the composition may have a viscosity of approximately 50 ⁇ 10 3 to 600 ⁇ 10 3 cPs at 25° C. In some embodiments, the viscosity may be 100 ⁇ 10 3 to 500 ⁇ 10 3 cP s at 25° C. In some embodiments, the viscosity may be 300 ⁇ 10 3 to 400 ⁇ 10 3 cPs at 25° C. In some embodiments, the viscosity may be 100 ⁇ 10 3 to 300 ⁇ 10 3 cPs at 25° C.
• the variation in viscosity may be due to specific applications where a more runny composition is preferred while other applications may require a more viscous composition.
• the composition may easily be made with a lower and higher viscosity as well without departing from the scope of the invention.
• another gel product, SolositeTM has a viscosity of 45-90 ⁇ 10 3 cPs at 25° C.
• the composition includes at least one topical carrier or vehicle.
• carriers or vehicles may be used.
• the at least one carrier or vehicle may have a melting point of about 37° C. or greater.
• Preferred carriers or vehicles understood by the applicant to be useful may include those selected from the group consisting of: a fatty ester, synthetic wax, beeswax, vegetal wax, mineral wax, a spermaceti wax constituent, carnauba wax and jojoba liquid wax.
• the topical carrier or vehicle is myristyl myristate.
• Myristyl myristate is a natural vegetable derived ester compound with emulsifier and opacifier characteristics. Myristyl myristate is often used in skin lotions to improve the feel of the compositions as it has the effect of thickening compositions. Myristyl myristate is an ester of myristic acid, which occurs naturally in animal or vegetable fats and oils.
• the at least one topical carrier or vehicle comprises from about 10% to about 30% wt of the composition. More specifically, the at least one topical carrier or vehicle comprises about 15% wt of the composition.
• honey naturally includes water (up to 18% wt.). Therefore, in order to combine and stabilise a myristyl myristate and honey emulsion, a surfactant l emulsifier is required.
• Olive oil used in the art is an oil and is not soluble in water. Due to these properties, olive oil will only mix with melted myristyl myristate, but not the honey. In the absence of a surfactant, once the mixture is cool, myristyl myristate will go back to its solid phase, but will not be fully dispersed within the honey. Instead, the myristyl myristate and olive oil exist as a separate phase.
• use of a surfactant and the type of surfactant is of importance.
• the carbon chain length of the tail of the fatty alcohol may be from about 6 carbon atoms to about 10 carbon atoms long. In some embodiments, the carbon chain length tail may be 7 to 9 carbon atoms long. In some embodiments, the carbon chain length tail may be 8 carbon atoms long.
• non-limiting examples of short chain fatty alcohols may be selected from the group consisting of: caprylyl capryl glucoside, coco glucoside, lauryl glucoside, cetearyl olivate, sorbitan olivate, polyglyceryl-6 caprylate, polyglyceryl-5 laurate, polyglyceryl-10 laurate, polyglyceryl-5 oleate, polyglyceryl-5 dioleate, polyglyceryl-10 diisostearate, polyglyceryl-3 stearate, polyglyceryl-3 palmitate, polyglyceryl-3 polyricinoleate, glyceryl oleate, sodium stearoyl lactylate, glyceryl stearate citrate, and combinations thereof.
• the naturally derived short chain fatty alcohol may be caprylyl capryl glucoside and derivatives thereof.
• This particular glucoside has been found by the applicants to confer the ideal properties to the composition including achieving the desired viscosity, the conversion from a gel to a skin on the wound when applied, the reduced stickiness of the composition, still allowing sufficient honey to be present in the composition to achieve the desired antibacterial function.
• the glucoside is natural based being plant derived and has non-ionic surfactant properties.
• caprylyl capryl glucoside was successful was unexpected as this type of glucoside is normally used in various foaming and cleaning compositions rather than wound care compositions owing to its surfactant and foaming characteristics.
• the surfactant properties appear to assist but foaming does not occur as in art compositions such as shampoos.
• use of glucoside and caprylyl capryl glucoside in particular conferred an improved stability, well beyond that found from other art compositions and beyond what might have been expected in the art based on published information about glucoside, particularly in combination with honey of which there is no known art to the applicant's knowledge.
• the composition contains from about 2% to about 10% wt naturally derived short chain fatty alcohol. More specifically, the composition contains from about 2% to about 7% wt naturally derived short chain fatty alcohol. In some embodiments, the composition contains about 4-6% wt naturally derived short chain fatty alcohol. In some embodiments, the composition may contain about 5% wt naturally derived short chain fatty alcohol.
• the honey used may have both peroxide and non-peroxide activity.
• Non-peroxide activity is often used interchangeably with the measurement of ‘unique manuka factor’ or UMF activity.
• Honey has inherent physical characteristics such as low pH and osmolarity that deter microbial growth however honeys with non-peroxide activity are often desired or preferred in medical applications due to the enhanced anti-microbial effects observed from such honeys including those honeys derived from the species Leptospermum and specifically either Leptospermum scoparium or manuka honey and/or Leptospermum polygalifollum or jellybush honey.
• the composition may constitute approximately 70-90% wt honey. As should be appreciated, this is ample honey and ensures activity well beyond that of more dilute formulations with less than 50% wt such as those taught in the art.
• honey has been used, a honey derivative or honey analogue may equally be used without departing from the scope of the invention.
• the sterilisation effective dose as noted above may be greater than 10 kGy. In some embodiments the dose may be greater than 20 kGy. In some embodiments, the dose may be greater than 30 kGy. In some embodiments, the dose may be 32.5 kGy to 60 kGy.
• irradiation of the composition does not appreciably alter the stability and physical characteristics of the composition unlike some art compositions that become unstable and separate post irradiation treatment. Irradiation is important in many applications such as medical applications to ensure that there are no residual microbes that may cause infection of a wound.
• the pH of the composition also remains stable during storage.
• the pH of the composition post manufacture and during storage may be between 3.0 and 60.
• the pH may be 3.0 to 5.0.
• the pH may be 4.0 to 5.0.
• the pH remains within the specified range for the duration of storage.
• the composition is irradiated with a sterilisation effective dose of radiation.
• the composition is a gel with similar viscosity to that described above.
• the above embodiments have the same stability characteristics as that described above including stability for at least 8 days when stored at 40° C.
• the intended use of the gel composition described herein is as a wound gel that is ideally applied to wounds as a gel.
• the myristyl myristate or other wax helps to provide the gel consistency but without a surfactant, the myristyl myristate will not disperse into the emulsion. Instead, if it mixes at all, it will exist in the mixture as hard globules within a matrix of liquid honey. This will fail the required outcome as, in the wound, once the honey melts due to the amount of exudate, the waxes will stick to the wound bed and will be hard to wash away.
• a non-ionic surfactant being a short chain fatty acid and, in some embodiments being caprylyl capryl glucoside, meets the desired criteria well including conferring longevity during storage.
• honey manufactured with a UMF level of 12+
• myristyl myristate (15% wt)
• caprylyl capryl glyceride 5% wt
• the pH of the composition was 3.5-4.5 and an antibacterial activity >10% phenol equivalent or >10 UMF activity over the shelf life.
• honey jellybush honey with a UMF level of 12+
• myristyl myristate (15% wt)
• caprylyl capryl glucoside 5% wt
• the pH of the composition was 3.5-4.5 and an antibacterial activity >10% phenol equivalent or >10 UMF activity over the shelf life.
• Example 1 the composition of Example 1 was stored at freezer temperatures ( ⁇ 18° C.) and at high temperature (40° C.) for 21 days and measurements of colour, odour, appearance, texture and phase separation tested at time zero and after 3 weeks. These temperatures were chosen to simulate either extreme of shipping temperature.
• Example 1 the composition of Example 1 was stored at an elevated temperature 40° C. for one week and then at 30° C. for a further 5 to 8 weeks and measurements of colour, odour, appearance, texture, phase separation, pH were tested at time zero, after 6 weeks and after 9 weeks. These temperatures were chosen to simulate a shipping temperature.
• Example 1 The composition described in Example 1 was tested by wound dressing clinicians and a clinical nurse with experience in the area of wound dressings and in particular honey based wound dressing gels.
• Example 4 a trial is presented where the stability at 40° C. of a composition of Example 1 is compared to a composition modelled on that described in the art, specifically U.S. Pat. No. 6,482,442 (two formulations) and U.S. Published Application No. 2010/0233283.
• the specific amounts and a compounds used in each composition are shown in Table 4 below.
• Example 1 composition was mixed, irradiated and then stored at 40° C. When the trial ended at Day 8, the Example 1 composition had identical characteristics to that at the start of the trial, remaining stable for the 8-day duration.
• the composition based on US '283 was mixed together and irradiated in the same manner as the composition of Example 1. Initial characteristics of the US '283 composition were the same as that of the Example 1 composition at the beginning of the trial. However, within a 12 hour time period, the US '283 composition separated and hence was unstable at elevated storage temperatures.
• compositions based on US '442 were highly unstable. Neither sample could be mixed together even before irradiation took place, in the case of the US '442 Composition 1 mixture, despite vigorous mixing the oil formed a separate layer on the top of the honey and myristyl myristate. In the case of the US '442 Composition 2 mixture, again despite vigorous mixing, the myristyl myristate formed a separate layer on the top of the honey and oil.
• the microbial growth stability of the composition was tested to confirm that, post storage, microbial growth did not occur. As may be appreciated, particularly for medical applications, microbial growth is of significant concern and must be avoided.
• Example 1 A total of five separate samples were taken based on the composition described in Example 1. The samples were stored at 40° C. for 8 days. Following storage, the samples were stored aseptically and transported to a laboratory where they were analysed for microbial growth by reference to tests for:
• honey manufactured with a UMF level of 12+
• myristyl myristate (15% wt)
• caprylyl capryl glucoside 5% wt
• the trial comprised of two tests, one being a comparison between samples stored at ⁇ 180 against the same sample stored at 40° C.
• a second trial studied the stability of the composition in an accelerated study with honey stored at 300.
• Table 5 below shows the results of the first study while Table 6 below shows the results of the second study.
• composition is stable for at least 15 weeks when stored at 30° C. and illustrates minimal difference between freezer storage versus 40° C. storage.
• results when applied to more normal ambient conditions support a shelf life of at least 3 years.
• Example 7 Samples produced as per Example 1 were stored at 40° C. for 48 hours, 7 days, 14 days and 28 days and at each stage tested for microbial count. The initial inoculum and a time zero count were also measured. The results found are illustrated in Table 7 below.
• composition in accordance with embodiments described herein had an immediate and catastrophic effect on microbial growth with microbes tested being killed to less than detectable levels within 48 hours. This effect is the same as that observed using honey hence it can be concluded that the composition described herein retains the antibacterial effects of honey.
• Example 1 the viscosity of the composition described in Example 1 was tested. Three samples of the composition were tested and averaged to establish a viscosity figure. The method used a Brookfield Viscometer with Helipath Spindle F at 1.6 rpm and 25° C.
• Viscosity Measurements Sample Number Viscosity [cPs @ °25] 1 254000 2 210000 3 454000 4 180000 5 423000 6 168000 7 158000 8 158000 9 189200

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Insects & Arthropods (AREA)
• Engineering & Computer Science (AREA)
• Dermatology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Molecular Biology (AREA)
• Animal Husbandry (AREA)
• Emergency Medicine (AREA)
• Zoology (AREA)
• Materials Engineering (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicinal Preparation (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Related Parent Applications (2)

Related Child Applications (1)

Publications (1)

Family

ID=44763131

Family Applications (3)

Family Applications After (2)

Country Status (5)

Cited By (4)

Families Citing this family (3)

Citations (1)

Family Cites Families (5)

• 2011
  • 2011-04-07 WO PCT/NZ2011/000049 patent/WO2011126384A1/fr active Application Filing
  • 2011-04-07 CA CA2793354A patent/CA2793354C/fr active Active
  • 2011-04-07 US US13/637,261 patent/US20130039992A1/en not_active Abandoned
  • 2011-04-07 EP EP11766211.4A patent/EP2555784B1/fr active Active
  • 2011-04-07 AU AU2011238996A patent/AU2011238996B2/en active Active
• 2015
  • 2015-11-16 US US14/942,721 patent/US10765707B2/en active Active
• 2020
  • 2020-08-03 US US16/983,975 patent/US20210052668A1/en not_active Abandoned

Patent Citations (1)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events